SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Seribantumab (Primary) ; Docetaxel; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SHERLOC
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 According to a Merrimack Pharmaceuticals media release, planned number of patients changed from 80 to 100.
    • 29 Jan 2018 Last checked against Clinicaltrials.gov record.
    • 22 Jan 2018 The protocol has been amended to remove Pemetrexed (comparator) from the study. Also the planned patient number has decreased to 80.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top